A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

You may be eligible if

• 1. Patient aged ≥ 18 years
• 2. Written informed consent by the patient or the patient's legally authorized representative
• 3. Patient with histologically/cytologically confirmed diagnosis of NHL or CLL
• 4. Patient with relapsed or refractory disease who has no available therapeutic options known to provide clinical benefit
• 5. Patient who has measurable disease
• 6. All acute toxic effects of any prior antitumor therapy, including investigational therapy, resolved to Grade ≤ 1 before the start of study therapy
• 7. Eastern Cooperative Oncology Group Performance Status 0 to 2
• 8. Adequate bone marrow, renal and hepatic functions
• 2. Patient with central nervous system involvement
• 3. Patient with systemic and active infection
• 4. Any serious or uncontrolled medical disorder that may increase the risk associated with study participation or study treatment, or interfere with the interpretation of study results
• 5. Prior treatment with a MALT1 inhibitor
• 6. Patient receiving any other investigational drug within 4 weeks prior to study entry
• 7. Patient is unable to swallow tablets
• 8. Patient is found to be otherwise ineligible for the study by the investigator or sub investigator